Eosinophilic Esophagitis Market Size – By Drug Class, By Route of Administration, By Age Group, By Distribution Channel – Global Forecast, 2025 – 2034

Eosinophilic Esophagitis Market Size

The global eosinophilic esophagitis market size was valued at USD 366.2 million in 2024 and is estimated to grow at a CAGR of 31.4% from 2025 to 2034. The rising incidence and prevalence of eosinophilic esophagitis globally is one of the primary drivers of market growth.
 

Eosinophilic esophagitis is a chronic immune system disease. With this disease, a type of white blood cell, called an eosinophil, builds up in the lining of the tube that connects the mouth to the stomach. This tube is also called the esophagus. This buildup, which is a reaction to foods, allergens, or acid reflux, can inflame or injure esophageal tissue. Eosinophilic esophagitis is becoming increasingly recognized, particularly in western countries. The condition is more common in children and young adults but can affect individuals of any age.
 

For instance, according to a study published in the American Journal of Gastroenterology, the prevalence of eosinophilic esophagitis in the U.S. has increased significantly, with an estimated prevalence of 56 cases per 100,000 people in the adult population. Additionally, in Europe, studies have also shown a rise in the prevalence of disease, particularly in countries like Sweden and the UK. Thus, the global increase in the prevalence of eosinophilic esophagitis coupled with advancement in diagnostic technologies, boost the growth of the market.
 

Furthermore, the market is bolstered by increasing awareness of eosinophilic esophagitis among both healthcare providers and the public that contribute to the increase in demand for new therapeutics options such as target specific drugs that promotes the growth of the market. For instance, a survey conducted by Deloitte in 2021 showed that about 30% of primary care physicians and gastroenterologists had become more aware of eosinophilic esophagitis due to educational programs and scientific publications in recent years. Thus, the rising awareness among healthcare providers and patients and availability of advanced treatment landscape with new therapeutic options such as monoclonal antibodies and biologics, improves treatment outcomes for patients boosting the market growth.
 

Eosinophilic Esophagitis Market Trends

• The development of new diagnostic tools and techniques, such as non-invasive biomarkers and improved endoscopic procedures, has significantly enhanced the detection and management of eosinophilic esophagitis that drive the growth of market.
   
• Also, the approval of new drugs by regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) has a direct impact on the market by making new therapies available to patients and increasing treatment accessibility which is anticipated to boost market growth. For instance, Tezepelumab, a novel biologic that targets thymic stromal lymphopoietin (TSLP), is also being evaluated for its potential in treating eosinophilic esophagitis. While not yet approved for eosinophilic esophagitis, its ongoing trials demonstrate an increasing interest in biologic treatments. Thus, the ongoing clinical trials to launch new drug formulations are driving innovation in the market.
   

Eosinophilic Esophagitis Market Analysis

Based on drug class, the global market is divided into biologics, corticosteroids, proton pump inhibitors, immunomodulators, and other drug class. The corticosteroids segment dominated the market and was valued at USD 137.3 million in 2024.
 

• Corticosteroids, such as fluticasone propionate and budesonide, are widely used in the treatment of eosinophilic esophagitis due to their powerful anti-inflammatory properties.
   
• Moreover, corticosteroids offer rapid relief from the symptoms of eosinophilic esophagitis, such as dysphagia (difficulty swallowing), chest pain, and food impact, making them first-line treatment in many cases. This contributes to their widespread use in the management of disease, especially when combined with dietary modifications and other therapies.
   
• Furthermore, the growing adoption of corticosteroid therapies in developing markets owing to increase in awareness and the management of disease boost market growth.

Based on the route of administration, the global eosinophilic esophagitis market is categorized into injectable, oral, injectable, and topical. The oral segment accounted for the highest market share of 41.5% in 2024.
 

• The oral route is non-invasive, making it easier for patients to self-administer drugs compared to injections or intravenous (IV) routes.
   
• The development of novel oral biologics and small molecules targeting specific pathways in eosinophilic esophagitis (such as IL-4, IL-5, or IL-13) has expanded the treatment options. Oral therapies, such as oral corticosteroids, are more effective in controlling symptoms, thereby contributing to the segmental growth.
   
• Moreover, oral medications are formulated to target the esophagus and can reduce the systemic side effects. Thus, oral therapies allow for safer long-term use compared to systemic treatments, which can result in significant side effects over time.
   

Based on age group, the global eosinophilic esophagitis market is categorized into pediatric, adults, and geriatric. The adults segment dominated the market in 2024 and is growing with a CAGR of 31.5% during the analysis period.
 

• Eosinophilic esophagitis is increasingly diagnosed in adults, contributing to market growth. Additionally, the prevalence of adult eosinophilic esophagitis is rising, due to better diagnostic methods, increased awareness, and a broader understanding of the disease's impact beyond childhood.
   
• Eosinophilic esophagitis has historically been underdiagnosed by adults, but growing awareness among physicians and patients has led to increased diagnoses that further supports the growth of the market.
   
• Moreover, environmental factors, such as increased exposure to allergens and food triggers, are suspected to be contributing to the rise of eosinophilic esophagitis, particularly in adults.
   
• Furthermore, diet, environmental allergens, and genetic predispositions are some of the factors that are increasingly linked to eosinophilic esophagitis in adult population, leading to increasing demand for novel drug therapies, which boost market growth.
   

Based on distribution channel, the eosinophilic esophagitis market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2024 and is anticipated to reach USD 2.1 billion by 2034.
 

• With the increasing awareness of eosinophilic esophagitis, more patients seek diagnosis and treatment, which is typically initiated in hospital settings. Advanced diagnostic techniques such as endoscopy and biopsy are increasingly used in hospitals, prompting the need for specialized medications, contributing to segmental growth.
   
• Additionally, hospital pharmacies are often the first point of contact for patients receiving new and emerging treatments for eosinophilic esophagitis, such as biologic therapies like Dupixent (dupilumab).
   
• Moreover, hospital pharmacies are expected to see growth due to the rising adoption of targeted therapies, such as corticosteroids and biologics. These therapies are often prescribed by specialists and require careful monitoring, which hospitals are equipped to manage.

In 2024, the U.S. held a significant position in the North America eosinophilic esophagitis market and was valued at USD 151.3 million.
 

• Eosinophilic esophagitis is more commonly diagnosed in the U.S. due to increased awareness and better recognition. The prevalence is increasing, particularly among children and young adults, that further contribute to market growth.
   
• U.S. healthcare spending continues to increase, with a focus on rare and chronic conditions such as eosinophilic esophagitis. Healthcare providers are investing in the development of innovative treatments, and patients are increasingly seeking effective long-term management solutions.
   
• Moreover, there has been a surge in funding for research into pathophysiology, diagnosis, and treatment of eosinophilic esophagitis. As a result, the U.S. is seeing more clinical trials and studies focusing on the disease, contributing to the development of new therapeutic approaches.
   

Germany shows strong growth potential in the eosinophilic esophagitis market.
 

• The incidence of eosinophilic esophagitis in Germany, as well as in other parts of Europe, has been increasing. For instance, according to a study published in European Journal of Gastroenterology & Hepatology (2021), the incidence of eosinophilic esophagitis in Europe is estimated to be between 1 and 5 per 100,000 individuals, with Germany falling in the middle of this range.
   
• Thus, the increase in prevalence coupled with change in lifestyle such as rise in westernized diets, environmental factors contributing to a higher number of individuals with allergic diseases, such as eosinophilic esophagitis is one of the primary factors driving the market growth.
   
• Moreover, Germany has a well-established healthcare system, where endoscopic procedures are widely available. The German medical community has been increasingly emphasizing the early diagnosis of eosinophilic esophagitis, which requires the use of endoscopic techniques for accurate assessment and biopsy.
   

The eosinophilic esophagitis market in Asia Pacific is estimated to grow at a CAGR of 31.8% over the next few years.
 

• The healthcare system in China has been undergoing significant reform and improvement in recent years, providing better access to diagnostic tools such as endoscopy and biopsy procedures to diagnose eosinophilic esophagitis.
   
• Moreover, the Chinese government has been supporting clinical trials and research through funding, particularly in the field of rare diseases and chronic conditions like eosinophilic esophagitis. The development of Chinese guidelines for managing allergic diseases is also likely to help improve patient outcomes and market growth.
   
• The increasing elderly population in China and rapid increase in urbanization leads to a greater number of people adopting sedentary lifestyles, which can exacerbate conditions like obesity and gastrointestinal diseases, leading to an increase in eosinophilic esophagitis, which propel the market growth.
   

Brazil's eosinophilic esophagitis market is projected to witness growth in coming years.
 

• Brazil’s rapidly changing dietary patterns, with increased consumption of processed foods and allergens, are contributing to a rise in eosinophilic esophagitis cases. Environmental factors, such as exposure to allergens, may also be increasing.
   
• Furthermore, the Brazilian government has been focusing on improving chronic disease management, including conditions like eosinophilic esophagitis. Additionally, initiatives aimed at better diagnostic infrastructure and funding for chronic illness management are expected to boost the market.
   

Saudi Arabia is anticipated to grow in the Middle East and African eosinophilic esophagitis market.
 

• Saudi Arabia has observed a rise in allergic conditions, including food allergies, which are linked to eosinophilic esophagitis. The increasing prevalence of these allergies contributes to a higher incidence of eosinophilic esophagitis cases, thereby expanding the patient population requiring treatment.
   
• Moreover, Saudi Arabia has been investing in its healthcare infrastructure, leading to improved diagnostic capabilities and better patient care. Enhanced awareness among healthcare providers and the public about eosinophilic esophagitis contributes to earlier diagnosis and treatment, positively impacting the market.
   

Eosinophilic Esophagitis Market Share

The competitive landscape in the market is characterized by a mix of global pharmaceutical and biotechnology companies and regional players. Established pharmaceutical giants offer well-known eosinophilic esophagitis under various brand names. Companies are focusing on product differentiation, regulatory approvals, and strategic partnerships to strengthen their position in this competitive market.
 

Eosinophilic Esophagitis Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are in clinical phase development. Players operating in the market are as mentioned below:

• Allakos
• Arena Pharmaceuticals
• AstraZeneca
• Cipla
• Ellodi Pharmaceuticals
• EsoCap
• GlaxoSmithKline
• Revolo Biotherapeutics
• Sanofi
• Sun Pharmaceutical
• Takeda Pharmaceutical Company
• Teva Pharmaceutical 
   

Eosinophilic Esophagitis Industry News

• In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), for people 11 years and older with eosinophilic esophagitis. This helped the company expand its product range.
   
• In January 2024, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis. This approval aimed to broaden the treatment availability, complementing existing therapies for eosinophilic esophagitis.
   

The eosinophilic esophagitis market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Biologics
• Corticosteroids
• Proton pump inhibitors
• Immunomodulators
• Other drug class

Market, By Route of Administration

• Oral
• Injectable
• Topical

Market, By Age Group

• Pediatric
• Adults
• Geriatric

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE